Advertisement
Screener

ALTIMMUNE, INC. (ALT) Loss Contingency, Estimate of Possible Loss

1.1 / 5 stars · 19/86 Roast Me

ALTIMMUNE, INC. Loss Contingency, Estimate of Possible Loss

ALTIMMUNE, INC. (ALT) had Loss Contingency, Estimate of Possible Loss of $113.10 million as of 2015-01-31, per its 10-K filed 2017-03-14.

Discontinued › Notes › Commitment and Contingencies › Loss Contingency

us-gaap:LossContingencyEstimateOfPossibleLoss · last filed 2017-03-14

  • 2015-01-31: Loss Contingency, Estimate of Possible Loss $113.10M.
  • 2015-01-15: Loss Contingency, Estimate of Possible Loss $113.10M.
  • 2015-01-07: Loss Contingency, Estimate of Possible Loss $113.00M.
Period endLoss Contingency, Estimate of Possible Loss
2015-01-31$113.10M
10-K · filed 2017-03-14
2015-01-15$113.10M
10-Q · filed 2015-11-06
2015-01-07$113.00M
10-Q · filed 2015-11-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
Monopar Therapeutics (MNPR)United States$0.598B-34.82
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
CorMedix Inc. (CRMD)United States$0.605B3.25
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76
Neurogene Inc. (NGNE)$0.625B-4.46
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
Indaptus Therapeutics, Inc. (INDP)United States$0.537B